Nuclear-Targeted Drug Delivery Systems for Cancer Therapy: Advances, and Challenges.

Yonghui Liu, Yanan Wu, Yifan Wu, Dong Wan, Cheng Zhang, Yongzhen Pei, Jie Pan

Abstract readReview

In one paragraph

Review in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yonghui LiuSchool of Chemistry, Tiangong University, Tianjin 300387, China.

Yanan WuSchool of Chemistry, Tiangong University, Tianjin 300387, China.

Yifan WuSchool of Chemistry, Tiangong University, Tianjin 300387, China.

Dong WanSchool of Chemical Engineering and Technology, Tiangong University, Tianjin 300387, China.

Cheng ZhangSchool of Chemistry, Tiangong University, Tianjin 300387, China.

Yongzhen PeiSchool of Mathematical Sciences, Tiangong University, Tianjin 300387, China.

Jie PanSchool of Chemistry, Tiangong University, Tianjin 300387, China.ORCID 0000-0002-6767-6932

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development of nuclear-targeted drugs has provided a more favorable option for tumor therapy. However, multiple biological barriers in vivo greatly reduce the efficiency of drug entry into the nucleus, rendering tumor therapy largely ineffective. Notably, the nucleus remains a critical therapeutic target, as most anticancer agents exert their effects through direct interactions with nuclear DNA or inhibition of topoisomerase activity, thereby disrupting DNA structure and impeding replication/transcription processes. This review systematically examines advanced delivery strategies for nuclear-targeted drug systems, explores their diverse therapeutic applications in oncology, and analyzes current challenges alongside future opportunities to guide the development of next-generation intelligent nuclear delivery platforms.

Indexed as

Antineoplastic AgentsCell NucleusDrug Delivery SystemsNeoplasmsAnimalsHumansAntineoplastic Agentsanticancercontrolled releasedrug delivery systemnuclear-targetedtumor therapy

Identifiers

PMID42123803

DOI10.3390/molecules31091437

PMCPMC13164812

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.